State of Alaska Department of Revenue Cuts Position in Gilead Sciences, Inc. $GILD

State of Alaska Department of Revenue decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 160,773 shares of the biopharmaceutical company’s stock after selling 9,210 shares during the quarter. State of Alaska Department of Revenue’s holdings in Gilead Sciences were worth $19,732,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Invesco Ltd. increased its position in shares of Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after acquiring an additional 1,618,453 shares during the period. Legal & General Group Plc increased its position in shares of Gilead Sciences by 4.2% during the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after acquiring an additional 414,454 shares during the period. Ameriprise Financial Inc. increased its position in shares of Gilead Sciences by 5.9% during the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock worth $793,506,000 after acquiring an additional 400,002 shares during the period. Nordea Investment Management AB increased its position in shares of Gilead Sciences by 16.5% during the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after acquiring an additional 726,101 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after acquiring an additional 4,113,999 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GILD. Deutsche Bank Aktiengesellschaft upped their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Rothschild & Co Redburn upped their price objective on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Truist Financial upped their price objective on Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Finally, The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $156.42.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the sale, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 299,280 shares of company stock valued at $42,820,550 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Tubulis for up to $5 billion to expand its ADC oncology pipeline — a strategic bolt-on that supports Gilead’s shift into oncology and could drive longer‑term revenue growth. Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
• Positive Sentiment: Gilead exercised its option to license KT‑200 from Kymera, triggering a $45M milestone payment to Kymera and adding a first‑in‑class oral CDK2 degrader to its discovery-to-clinic pipeline — a validation of Gilead’s external innovation strategy. KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
• Positive Sentiment: Research partners and collaborations: expanded RWE and oncology R&D tie-ups (Tempus, Cartography) reinforce Gilead’s push to accelerate translational work and de‑risk discovery-stage assets. Tempus Announces Strategic Collaboration with Gilead
• Positive Sentiment: Sell-side lifts and bullish notes: Morgan Stanley raised its price target to $175 with an overweight rating (largest upside among today’s notes), and Truist also nudged up its target — these analyst actions can support buying interest. Price target raise at Morgan Stanley (Benzinga)
• Neutral Sentiment: Short‑interest data for April is effectively meaningless/zero in the report (shows 0 shares / NaN change), so it doesn’t provide directional insight into current positioning.
• Negative Sentiment: Cantor Fitzgerald cut its price target sharply to $115 (while oddly maintaining an overweight rating), introducing downside headline risk and signaling divergent analyst views on valuation. Cantor Fitzgerald Adjusts Price Target on Gilead Sciences
• Negative Sentiment: The AIDS Healthcare Foundation publicly criticized Gilead over its role in a Florida drugs situation — reputational and regulatory scrutiny can pressure sentiment and potentially elevate legal/regulatory risk. AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Gilead Sciences Stock Performance

NASDAQ GILD opened at $139.03 on Monday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a market capitalization of $172.56 billion, a PE ratio of 20.54, a P/E/G ratio of 1.85 and a beta of 0.39. The company has a fifty day moving average of $145.13 and a two-hundred day moving average of $130.59.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date was Friday, March 13th. Gilead Sciences’s payout ratio is currently 48.45%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.